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Introduction: Urokinase-type plasminogen activator (uPA) is a protease
associated with tumor metastasis and invasion. Inhibitors of uPA may have
potential as drugs for prostate, breast and other cancers. Therapeutically useful
inhibitors must be selective for uPA and not appreciably inhibit the related, and
structurally and functionally similar enzyme, tissue-type plasminogen activator
(tPA), involved in the vital blood-clotting cascade.
Results: We produced mutagenically deglycosylated low molecular weight uPA
and determined the crystal structure of its complex with 4-iodobenzo[b]thiophene-
2-carboxamidine (Ki = 0.21 ± 0.02 µM). To probe the structural determinants of
the affinity and selectivity of this inhibitor for uPA we also determined the
structures of its trypsin and thrombin complexes, of apo-trypsin, apo-thrombin and
apo-factor Xa, and of uPA, trypsin and thrombin bound by compounds that are
less effective uPA inhibitors, benzo[b]thiophene-2-carboxamidine, thieno[2,3-b]-
pyridine-2-carboxamidine and benzamidine. The Ki values of each inhibitor toward
uPA, tPA, trypsin, tryptase, thrombin and factor Xa were determined and
compared. One selectivity determinant of the benzo[b]thiophene-
2-carboxamidines for uPA involves a hydrogen bond at the S1 site to OγSer190 that
is absent in the Ala190 proteases, tPA, thrombin and factor Xa. Other subtle
differences in the architecture of the S1 site also influence inhibitor affinity and
enzyme-bound structure.
Conclusions: Subtle structural differences in the S1 site of uPA compared with
that of related proteases, which result in part from the presence of a serine
residue at position 190, account for the selectivity of small thiophene-
2-carboxamidines for uPA, and afford a framework for structure-based design of
small, potent, selective uPA inhibitors. 
Introduction
One of the basic hurdles in the development of enzyme
inhibitors as drugs involves the achievement of selectivity
toward the target enzyme and against its closely related
counterparts. In serine proteases specificity of a physiological
substrate is conferred by the combination of interactions at a
series of sites, designated S3, S2, S1, S1′, S2′ and S3′, that
bind successive peptide sidechains designated P3, P2 and P1
prior to the susceptible scissile peptide bond, and P1′, P2′
and P3′ after it [1]. Most inhibitors of a subset of trypsin-like
serine proteases (which includes trypsin, tryptase, factor Xa,
thrombin, urokinase-type plasminogen activator and tissue-
type plasminogen activator) have a basic group that makes
hydrogen-bonded salt bridges with the Asp189 carboxylate
at the base of the S1 pocket, as for the arginine residue of a
substrate. Interactions at the S1 site enable substrates or
inhibitors to discriminate between the class of trypsin-like
serine proteases with an aspartate residue at position 189 and
other families such as chymotrypsin-like proteases, with a
serine residue at position 189.
Selectivity of inhibitors for individual members within the
family of trypsin-like serine proteases is often achieved
through interactions of inhibitor groups at subsites such as
S1′, S2 and S3, whose sequences and structures differ sig-
nificantly from one member to the next [2–5]. Because of
the high structural similarity in the S1 sites of the trypsin-
like serine proteases with an aspartate residue at position
189, small-molecule inhibitors that achieve specificity for
trypsin-like serine protease drug targets through interac-
tions at this site alone merit close scrutiny. One such
inhibitor is 4-iodobenzo[b]thiophene-2-carboxamidine, a
lead compound from a series of over 90 4-substituted
benzo[b]thiophene-2-carboxamidines reported in 1993 [6].
This compound stands out as a submicromolar competitive
inhibitor of urokinase-type plasminogen activator (uPA),
exhibiting selectivity for uPA and against plasmin, throm-
bin and tissue-type plasminogen activator (tPA).
Because of its involvement in tumor metastasis and inva-
sion, uPA has emerged as a drug target for development of
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therapeutics for prostate, breast and other cancers [7–11].
Therapeutic inhibitors of uPA should not appreciably
inhibit the closely related enzymes (thrombin and tPA
[12]), which are critical components of the blood-clotting
pathway. Both uPA and tPA share the same primary
physiological substrate (plasminogen) and inhibitor (plas-
minogen activator inhibitor), exhibit stringent specificity,
and share similar sequences and three-dimensional struc-
tures [12,13]. Determination of the structural basis for the
affinity and selectivity of 4-iodobenzo[b]thiophene-2-car-
boxamidine for uPA and against tPA and other related pro-
teases is therefore expected to provide insight for
structure-based design of selective, potent inhibitors of
uPA and other trypsin-like protease targets. 
To this end we determined the crystal structures of the
uPA, trypsin and thrombin complexes of 4-iodo-
benzo[b]thiophene-2-carboxamidine, and the Ki values of
this inhibitor for trypsin-like serine protease drug targets
and anti-targets: uPA, tPA, thrombin, factor Xa, tryptase
and trypsin. Structural determinants of the binding of
this scaffold were further examined by quantitating inhi-
bition of each of the enzymes by structurally related
analogs that are less effective inhibitors of uPA,
benzo[b]thiophene-2-carboxamidine, thieno[2,3-b]pyri-
dine-2-carboxamidine, and benzamidine, and by deter-
mining and comparing the structures of the uPA, trypsin
and thrombin complexes. Finally, structures of inhibitor-
free trypsin, factor Xa and thrombin were determined to
delineate and compare features of the apo-enzymes, such
as the ordered solvent structure at the S1 site that medi-
ates the binding of the inhibitors investigated. The
uPA–small-molecule structures of this study, involving
fully reversible active site inhibitors, are among the first
reported to date [11].
Although the S1 sites of uPA and tPA are structurally very
similar, the identity of residue 190 is an important feature
that distinguishes one from the other. uPA and tPA can be
considered archetypes of two classes of trypsin-like serine
proteases, those with a serine residue at position 190, such
as uPA, trypsin and tryptase, and those with an alanine
residue at position 190, such as tPA, thrombin and factor
Xa. The differences in the architectures and hydrogen-
bonding potentials of the S1 sites of these two protease
families, as visualized in the structures of representative
members determined here, both in the presence and
absence of S1-bound inhibitors, provide a basis for selec-
tivity development. Comparison within this set of struc-
tures of distinguishing features in the S1 site, such as its
width and depth, its spatial relationship to the active site,
and the nature and degree of its structural plasticity,
yields clues for achieving inhibitor selectivity. The com-
plementary structural and inhibition data of this study not
only form a framework for the structure-based develop-
ment of potent, selective uPA inhibitors, but also provide
insight into the design of inhibitors that discriminate
between these two large important classes of trypsin-like
serine proteases.
Results
Affinity and selectivity of benzo[b]thiophene-2-carbox-
amidine analogs for uPA and for other trypsin-like serine
proteases
We observed competitive inhibition by 4-iodobenzo-
[b]thiophene-2-carboxamidine of each member of a panel
of trypsin-like serine proteases comprising uPA, trypsin,
tryptase, tPA, thrombin and factor Xa. The inhibition con-
stant (Ki value) determined here for uPA at pH 7.4 is
0.21 ± 0.02 µM (Table 1), compared with 0.53 ± 0.07 µM
determined at pH 7.5 by Towle et al. [6]. The Ki value for
tPA, an anti-target closely related structurally and func-
tionally to uPA, is 16.8 ± 0.4 µM, yielding a selectivity
ratio for tPA versus uPA of 80. Also listed in Table 1 are
the Ki values for benzo[b]thiophene-2-carboxamidine,
thieno[2,3-b]pyridine-2-carboxamidine and benzamidine
toward each protease. Our determined selectivity ratios of
4-iodobenzo[b]thiophene-2-carboxamidine toward uPA
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Table 1
Inhibition constants of amidine inhibitors toward selected trypsin-like serine proteases.
Ser190 proteases Ala190 proteases
Inhibitor uPA Trypsin Tryptase tPA Thrombin Factor Xa
APC-6860* 0.21 ± 0.02 0.44 ± 0.1 1.5 ± 0.1 16.8 ± 0.4 20 ± 2 30 ± 2
APC-7377† 2.3 ± 0.2 1.0 ± 0.1 9.9 ± 0.8 15 ± 1 58 ± 5 21 ± 2
APC-7538‡ 63 ± 5 80 ± 5 34 ± 2 1800 ± 100 1600 ± 200 360 ± 110
Benzamidine 97 ± 9 21 ± 2 20 ± 2 750 ± 70 320 ± 25 110 ± 20
None apo apo apo
All Ki values in µM. Bold values denote structures determined here or
elsewhere (tPA–benzamidine) [12]. *4-Iodobenzo[b]thiophene-2-
carboxamidine. Competitive inhibition was demonstrated and Ki values
determined rigorously for each enzyme by varying both the substrate
and the inhibitor concentrations. For the other compounds, Ki values
were determined at one substrate concentration (per enzyme) set near
the determined Km value (see text). †Benzo[b]thiophene-2-
carboxamidine. ‡Thieno[2,3-b]pyridine-2-carboxamidine.
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and against plasmin (15, data not shown), thrombin and
tPA (95 and 80, respectively) are significantly less than the
corresponding values in the study of Towle et al. (1100,
> 780 and 330, respectively) [6].
4-Iodobenzo[b]thiophene-2-carboxamidine is a signifi-
cantly better inhibitor of the Ser190 proteases listed in
Table 1, uPA, trypsin and tryptase (Ki = 0.2–1.5 µM), than
the Ala190 counterparts, tPA, thrombin and factor Xa
(Ki = 17–30 µM). In general, the other inhibitors in
Table 1 show a similar trend. Factors other than the iden-
tity of residue 190 can also influence inhibitor potency,
however. For example, benzo[b]thiophene-2-carboxami-
dine is a 9.9-fold better inhibitor of trypsin (1.0 µM) than
of tryptase (9.9 µM), both of which have a serine residue
at position 190. In addition, uPA (with Ser190) is inhibited
by benzamidine (Ki = 97 µM) about as weakly as is factor
Xa (with Ala190; Ki = 110 µM).
Benzo[b]thiophene-2-carboxamidine is a poorer inhibitor
of uPA and tryptase than the 4-iodo analog, by factors of
11 and 6.6, respectively (Table 1). The 4-iodo substituent
has little effect on the Ki values of the other proteases.
Introduction of a nitrogen into the six-membered ring of
benzo[b]thiophene, in thieno[2,3-b]pyridine-2-carboxami-
dine, leads to a decrease in affinity toward all of the
enzymes that ranges from as little as 3.4-fold for tryptase
to as much as 120-fold for tPA.
Benzo[b]thiophene-2-carboxamidines bound to uPA make
a hydrogen bond with Ser190 that is absent in Ala190
counterparts
Figure 1a shows the structure of uPA–4-iodobenzo[b]thio-
phene-2-carboxamidine, pH 6.5, superimposed on the
(2|Fo|–|Fc|), αc map. The inhibitor amidine lies at the
bottom of the S1 site, making two hydrogen-bonded salt
bridges with the carboxylate of Asp189. One amidine
nitrogen also donates a hydrogen bond to the carbonyl
oxygen of Gly219. The remaining amidine hydrogen (H1)
is donated in a multi-centered hydrogen-bonding inter-
action to OγSer190 and to an ordered water (water1). The
hydrogen-bond parameters at the S1 site for this and other
structures are listed in Table 2.
In Figure 1b the structure of uPA–4-iodobenzo[b]thio-
phene-2-carboxamidine is superimposed on the corre-
sponding thrombin complex. As in the uPA and trypsin
complexes, a water co-bound at the S1 site mediates
inhibitor binding. The N1inhibitor–OγSer190 and water1–
OγSer190 hydrogen bonds present in the uPA and trypsin
complexes are absent in the thrombin complex, however,
because residue 190 is an alanine in thrombin. One of
the components (N1–OγSer190) of the multi-centered
enzyme–inhibitor hydrogen bond in the uPA and trypsin
complexes is therefore absent in the thrombin complex.
The remaining component (N1–water1) is shorter in the
thrombin complex (2.9 Å at pH 7.3) than in the uPA
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Figure 1
(a) Superposition of the structure of uPA–
4-iodobenzo[b]thiophene-2-carboxamidine,
pH 6.5, onto the (2|Fo|–|Fc|), αc map (1.75 Å
resolution). In this and other density figures
contours are at 1.0 σ (light orange), 2.4 σ
(red) and 3.8 σ (pink). The shorter
(N1–OγSer190) component of the 3-centered
hydrogen bond is yellow, the longer
(N1–water1) component is cyan.
(b) Superposition of the thrombin– and
uPA–4-iodobenzo[b]thiophene-
2-carboxamidine complexes. In this and other
figures comparing uPA with another structure,
carbon, oxygen and nitrogen atoms are green,
red and blue, respectively, for uPA, and light
green, orange and purple, respectively, for the
other complex. Residues common to both
structures are labeled in white, those unique
to uPA in light blue and those unique to the
other enzyme in orange. Hydrogen bonds at
S1 are light blue for uPA, and orange for the
other enzyme. The long (3.21 Å) N1–water
hydrogen bond in the uPA complex is cyan.
The directionalities of the hydrogen bonds
involving OγSer190 and OηTyr228 in the uPA
complex can be inferred from the following: a
well-ordered water donates one proton to
OAla183, and the other to Oδ1Asp189 (data not
shown). The other hydrogen bond to this
water, involving OηTyr228, is therefore donated
by OηTyr228, the HηTry228 proton lying in the
aromatic plane. OηTyr228 therefore accepts the
hydrogen bond from OγSer190. 
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complex (3.2 Å at pH 6.6) or than in the trypsin complex
(3.1 Å at pH 8.2, or 3.5 Å at pH 5.5). The N1–H1–Owater1
angle of this interaction is nonoptimal (~130°) and similar
in all complexes (Table 2).
The decrease in the N1–water1 hydrogen bond length in
thrombin–4-iodobenzo[b]thiophene-2-carboxamidine from
that in the corresponding uPA complex is accomplished by
a rotation of the inhibitor amidine group by 12° around the
thiophene–amidine bond; in the thrombin complex the
amidine is virtually coplanar with the thiophene
(dihedral = –1°). The change in the inhibitor geometry to
planarity in the thrombin complex is associated with an
increase in the N1–Oδ1Asp189 hydrogen bond from 2.8 Å in
the uPA complex to 3.1 Å in the thrombin complex. 
Interactions and environment of the iodo group in
4-iodobenzo[b]thiophene-2-carboxamidine complexes
The density corresponding to the iodo group is very
strong (23 σ in the uPA and trypsin complexes). The iodo
group occupies a cavity, making van der Waals contacts
with CδGln192 (3.7 Å), SγCys220 (4.2 Å), OGly216 (3.9 Å), and
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Table 2
Hydrogen bond lengths and angles, inhibitor dihedrals, and temperature factor of co-bound water at the S1 site.
(a) uPA, tPA, trypsin and thrombin complexes of benzo[b]thiophene-2-carboxamidine analogs and of benzamidine.
N2– N2– N1– N1– N1–H1– Inhibitor
pH Oδ2Asp189 OGly219 Oδ1Asp189 OγSer190 OγSer190 dihedral
uPA–APC-6860* 5.5 2.85(02) 2.77(02) 2.83(03) 2.72(05) 121(2) 11(3)
Thrombin–APC-6860 7.3 2.81 2.62 3.13 –1
Trypsin–APC-6860 8.2 2.87 2.76 3.09 2.92 111 5
Trypsin–APC-6860 5.5 2.85 2.66 2.81 2.77 129 18
Trypsin–APC-7377† 8.2 2.80 2.72 2.85 2.91 127 4
uPA–APC-7538‡ 5.5 2.83 2.79 2.80 2.63 116 9, 2‡
Trypsin–APC-7538 5.5 2.80 2.73 2.83 2.84 124 –11, –11‡
Trypsin–APC-7538 8.2 2.90 2.76 2.89 2.87 119 –11, –9‡
Trypsin–benzamidine§ 7.5 2.93(05) 2.68(09) 2.90(04) 2.88(11) 120(2) –20(2)
Thrombin–benzamidine 7.3 2.76 2.59 2.95 –7
uPA–benzamidine 5.5 2.94 2.74 2.88 2.52 115 5
tPA–benzamidine# 7.5 3.00 2.82 2.96 –3
(b) complexes plus inhibitor-free trypsin, thrombin, and factor Xa.
N1– N1–H1– OγSer190– OVal/Phe/Ile227– OTrp215– B
pH OH2 OH2 OH2 OH2 OH2 (H2O)
uPA–APC-6860 5.5 3.21(04) 130(8) 3.01(11) 3.18(13) 3.42(02) 29(1)
Thrombin–APC-6860 7.3 2.91 130 3.07 3.60 19
Trypsin–APC-6860 8.2 3.12 142 3.16 2.98 3.39 25
Trypsin–APC-6860 5.5 3.47 118 3.18 2.89 3.32 24
Trypsin–APC-7377 8.2 3.15 119 2.91 3.05 3.20 24
uPA–APC-7538 5.5 3.26 130 3.19 3.11 3.20 20
Trypsin–APC-7538 5.5 3.16 128 3.12 2.98 3.08 18
Trypsin–APC-7538 8.2 3.07 131 3.21 2.87 3.01 20
Trypsin–benzamidine 7.5 3.04(06) 142(6) 3.14(06) 2.87(05) 3.06(06) 18(2)
Thrombin–benzamidine 7.3 2.73 150 3.25 3.29 16
uPA–benzamidine 5.5 2.96 136 2.84 3.26 3.41 19
tPA–benzamidine 7.5 3.06 154 2.83 3.36 26
apo-trypsin 5.0 2.70 3.33 3.22 29
apo-trypsin 7.7 3.00 3.02 3.12 29
apo-thrombin 7.8 3.06 3.36 34
apo-factor Xa 7.5 2.76 3.20 41
Distances are in Å, temperature factors (B-values) in Å2, and the ring-
amidine dihedral in degrees. Standard deviations are in parentheses.
*APC-6860, 4-Iodobenzo[b]thiophene-2-carboxamidine. †APC-7377,
Benzo[b]thiophene-2-carboxamidine. ‡APC-7538,
Thieno-[2,3-b]pyridine-2-carboxamidine. The dihedral angles are for
conformations 1 and 2 (see text) §Ten structures (pH 7.00 to 8.25) of
resolutions higher than 1.5 Å. #1rtf [12].
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NGly219 (4.3 Å) in the uPA complex, and similar contacts in
the trypsin and thrombin complexes. The structure of
trypsin–benzo[b]thiophene-2-carboxamidine is virtually
identical to that of the 4-iodo analog complex.
Variability in the structures of bound amidine inhibitors 
Comparison of the structures of the inhibitor complexes
of uPA, tPA, trypsin and thrombin denoted by the bold
entries in Table 1 reveals a remarkable diversity in the
binding of such small inhibitors. The complexes can be
divided roughly into two groups based on the orientations
of the aromatic planes of the bound inhibitors. The
inhibitors in the first set are rotated by ~20° from those in
the second set around their long symmetry axis. Conse-
quently the amidines in the first set are rotated around
the amidine-aromatic bond by ~–20° from those in the
second set in order to maintain hydrogen-bonding inter-
actions at S1. The first set includes trypsin–, thrombin–
and uPA–4-iodobenzo[b]thiophene-2-carboxamidine, uPA–
thieno[2,3-b]pyridine-2-carboxamidine, and uPA– and
tPA–benzamidine; the second set trypsin– and thrombin–-
benzamidine, and trypsin–thieno[2,3-b]pyridine-carbox-
amidine. The aromatic amidine dihedrals for the bound
inhibitors range from –20° to +18° (Table 2). 
Diversity in the S1 site architectures of the trypsin-like
serine proteases complexes
Differences in the bound structure of benzamidine or of
other small amidine inhibitors among the trypsin-like pro-
tease complexes reflect subtle but significant changes in
the corresponding S1 site architectures. In uPA–benzami-
dine there are shifts (of ~0.5 Å) in the position of OγSer190,
OηTyr228, and water1 from the respective locations in
trypsin–benzamidine (Figure 2a, Table 3a). In trypsin–
benzamidine (and in many other trypsin–amidine com-
plexes) water1 makes four hydrogen bonds. In the hydro-
gen-bonding scheme of Figure 2a, water1 accepts
hydrogen bonds from OγSer190, (3.14 ± 0.06 Å) and from
N1benzamidine (3.04 ± 0.06 Å), and donates hydrogen bonds
to OTrp215 (3.06 ± 0.06 Å) and to OVal227 (2.87 ± 0.05 Å;
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Figure 2
(a) Superposition of the structures of trypsin–
benzamidine, pH 7.5, at 1.21 Å resolution, and
uPA–benzamidine, pH 6.5, at 1.85 Å
resolution. Hydrogen bonds for the trypsin and
uPA complexes are yellow and light blue,
respectively. The long water1–OVal227
interaction in uPA–benzamidine (3.26 Å) is
darker cyan. In addition to any hydrogen
bonds accepted from water1, the carbonyl
oxygens of residues 215 and 227 also accept
β-sheet hydrogen bonds, with better angular
components, from the peptide nitrogens of
residues 227 and 215, respectively, in these
and other structures. In the hydrogen-bonding
scheme shown, OγSer190 donates a multi-
centered hydrogen bond to water1 and to
OηTyr228. Other orientations of water1 and
alternate hydrogen bonding OγSer190–water1
directionalities are possible, especially in
cases where hydrogen bonds to the carbonyl
oxygens of residues 215 and/or 227 are
absent, as in Figure 1. (b) Superposition of
thrombin–benzamidine onto uPA–benzamidine
using corresponding mainchain atoms from
residues 43–45, 53, 54, 191–197, 212–221
and 227–229 yields a 0.25 Å rms deviation
between these two sets of atoms.
(c) Superposition of tPA–benzamidine (1rtf
[12]) onto uPA–benzamidine.
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Table 2). In uPA–benzamidine, however, the latter hydro-
gen bonds are absent (water1–OTrp215 = 3.4 Å, water1–
OVal227 = 3.3 Å). Their absence is associated with shorter
N1–OγSer190 and water1–OγSer190 hydrogen bonds (2.5 Å
and 2.8 Å) than in the other trypsin and uPA complexes
(Table 2). The difference in hydrogen-bonding interac-
tions involving water1 between uPA– and trypsin–benza-
midine is not seen between uPA– and trypsin–
4-iodobenzo[b]thiophene-2-carboxamidine. In both of the
latter complexes water1 makes hydrogen bonds with
OγSer190, N1 and OVal/Phe227, but not with OTrp215 (Table 2).
Table 3a lists the overall root mean square deviations
(rmsds) and selected individual atomic differences
between the superimposed inhibitor-binding sites of pairs
of benzamidine complexes of trypsin, uPA, thrombin and
tPA, along with the percent of sequence identity between
the catalytic domains (heavy chains) of each pair or
between their structural cores. There is a rough correlation
between overall (and core) sequence similarity and simi-
larity in the S1 site architecture. The two most structurally
similar S1 sites (rmsd 0.29 Å) belong to the pair of pro-
teases with the highest overall sequence identity,
uPA/tPA (45.6%). The largest structural variations
(rmsd 0.41 Å) occur for the pair with the second lowest
overall sequence identity, thrombin/tPA (31.5%,
Table 3a).
In each of the structures of this study the S1, S1′ and
active-site residues Cys42, His57, Asp189, Ser195 and
Tyr228, common to uPA, tPA, trypsin, tryptase, thrombin,
and factor Xa, are well determined by density and have low
temperature factors (Table S1b in the Supplementary
material section). The relative locations of selected atoms
of these residues vary significantly between complexes,
however, by as much as 1 Å (Table 3a), irrespective of the
identity of residue 190. The differences between proteases
in the sidechain position and conformation of Tyr228 can
be seen in Figure 2a–c for the comparisons of the benzami-
dine complexes of uPA, trypsin, thrombin and tPA. These
types of subtle differences define a unique set of S1 site
dimensions (Table S1a) that distinguish one protease from
another, providing a fingerprint of each particular protease.
Table 3c also summarizes some control comparisons.
Overall, there are minor differences between the benza-
midine-binding sites of trypsin crystal forms P3121 and
P212121, although some moderate and highly reproducible
differences do occur. Because neighboring protein mol-
ecules do not directly contact any of the bound inhibitors
or inhibitor-binding sites in either crystal form, the differ-
ences must reflect indirect, and relatively long-range
effects of crystal packing. Identical structures indepen-
dently determined in the same crystal form exhibit negli-
gible structural differences (rmsd 0.05 Å; Table 3c), and
emphasize the accuracy of the structural determinations.
A dramatic increase in the depth of the S1 site of uPA
compared with that of thrombin is apparent in the compar-
ison of the structures of uPA– and thrombin–benzamidine
(Figure 2b). Bound benzamidine is shifted by 0.5 Å, and
the Asp189 sidechain is correspondingly shifted by ~0.6 Å
(Table 3a). The relative positions of the bound inhibitors
and of the Asp189 sidechain are significantly different in
many of the comparisons that involve a common bound
inhibitor. The largest differences occur between uPA and
thrombin. By contrast, the structures of the S1 sites of uPA
and tPA are highly similar (Figure 3c) and have the lowest
overall rms deviations from one another, 0.29 Å
(Table 3a). Benzamidine binds in a similar relative posi-
tion and orientation, and with a similar planarity to these
two related proteases (Figure 3c). The high similarity of
the uPA– and tPA–benzamidine complexes underscores
the effect of residue 190 on inhibitor potency. The most
obvious difference between the complexes, the absence of
the Ser190 sidechain and of the associated hydrogen bond
to benzamidine in the tPA complex, is strongly implicated
in the 7.7-fold decrease in potency.
Discrete conformational disorder in thieno[2,3-b]pyridine-
2-carboxamidine bound to uPA and trypsin
In uPA–thieno[2,3-b]pyridine-2-carboxamidine, pH 6.5,
and in the corresponding trypsin complex, pH 5.5 and 8.2,
the inhibitor is discretely disordered between two confor-
mations involving a 180° rotation of the thieno[2,3-b]pyri-
dine moiety about the amidine–thiophene bond. The
disorder was discovered and verified as described in the
Supplementary material section. Figure 3a shows the
structure and (2|Fo|–|Fc|), αc map for uPA–thieno[2,3-b]-
pyridine-2-carboxamidine, pH 6.5. In the first conforma-
tion the sulfur is in a favorable location, as in bound
benzo[b]thiophene-2-carboxamidines. Water1 is shifted,
by 0.5 Å, from its position in uPA–4-iodobenzo[b]thio-
phene-2-carboxamidine, donating a shorter hydrogen
bond to the thiophene sulfur (3.0 Å versus 3.3 Å), and
coming into hydrogen-bonding range of OTrp215 (3.2 Å
versus 3.4 Å). In the first conformation of bound
thieno[2,3-b]pyridine-2-carboxamidine, the inhibitor nitro-
gen is not in a favorable location, buried without hydrogen
bonds, 3.6 Å from OγSer195. In the second conformation,
the nitrogen is in a more favorable location, exposed to
solvent but the sulfur is in a less favorable location,
making a close S–OGly219 contact (3.3 Å; Figure 3a). 
In trypsin–thieno[2,3-b]pyridine-2-carboxamidine, the
nitrogen of the second conformer does make a hydrogen
bond (3.1 Å) with OγSer195, because the bound inhibitor is
0.5 Å higher in the S1 site than in the uPA complex
(Figure 3b). At pH 8.2 it can be inferred that OγSer195 is
the hydrogen-bond donor to both Nε2His57 and to the
inhibitor nitrogen. Consequently there is a deficit in
hydrogen-bonding interactions involving the buried
inhibitor nitrogen, OγSer195 and Nε2His57. At pH 5.5 a
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sulfate is co-bound with partial occupancy (60%) at the
active site, receiving hydrogen bonds from Nε2His57,
OγSer195, and NGly193, as in trypsin–benzamidine-sulfate, or
–BABIM-sulfate [14] (Figure 3b). The Hγ proton of
Ser195 is disordered, donating partial hydrogen bonds to
two of the oxygens of the co-bound sulfate in one location,
and donating a hydrogen bond to the nitrogen of con-
former 2 of the inhibitor in the other location (Figure 3b).
(The pKa of the thieno[2,3-b]pyridine nitrogen is 
estimated to be ~4.9 [15].) The aromatic planes of the
inhibitor conformers in uPA–thieno[2,3-b]pyridine-2-car-
boxamidine are rotated ~17° from those in the trypsin–
thieno[2,3-b]pyridine-2-carboxamidine (Figure 3b), but
are oriented similarly to those in uPA– and trypsin–
4-iodobenzo[b]thiophene-2-carboxamidine. No binding of
thieno[2,3-b]pyridine-2-carboxamidine to thrombin was
observed crystallographically at an inhibitor concentration
of 1 mM.
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Table 3
Comparison of structures of benzamidine complexes of trypsin, uPA, thrombin, and tPA, and of apo-trypsin and apo-thrombin.
Sub-site S1
Residue Ser/Ala190 Asp189 Tyr228 Gly219 Inhibitor H2O(1)
Atom Oγ Cβ Oδ1 Oδ2 Oη Cε2 O N1 N2 O
(a) Thrombin/uPA 0.52 0.33 0.75 0.22 0.23 0.59 0.41 0.61 0.09
Thrombin/tPA 0.64 0.18 0.61 0.31 0.17 0.26 0.21 0.31 0.29
Trypsin/thrombin 0.50 0.22 0.55 0.82 0.67 0.35 0.21 0.22 0.65
Trypsin/uPA 0.52 0.22 0.30 0.38 0.52 0.49 0.20 0.50 0.31 0.45
Trypsin/tPA 0.65 0.16 0.21 0.77 0.58 0.25 0.25 0.28 0.46
uPA/tPA 0.43 0.25 0.29 0.54 0.37 0.37 0.55 0.10 0.30
(b) Trypsin/apo-trypsin 0.57 0.44 0.14 0.29 0.15 0.16 0.16 0.19
Thrmb/apo-thrombin 0.14 0.37 0.42 0.20 0.15 0.34 0.55
(c) Trypsin*, P3121/P212121 0.14 0.11 0.19 0.16 0.12 0.10 0.19 0.37 0.33 0.22
Trypsin†, P3121/P3121 0.12 0.05 0.05 0.05 0.05 0.02 0.10 0.05 0.06 0.05
Trypsin‡, +SO4–2/–SO4–2 0.09 0.05 0.05 0.04 0.03 0.06 0.05 0.05 0.04 0.04
Sub-site S1′ Active site Sequence
Residue Cys42 Ser195 His57 Gln/Glu192 Residues withheld identity
Atom N Oγ Cβ Nε2 Cα from superposition§ rmsi§ rmsf§ Overall  Core#
(a) Thrombin/uPA 0.40 1.07 0.24 1.07 0.56 42, 57–58, 189–190, 192–193 0.36 0.25 27.8 44.1
Thrombin/tPA 0.74 0.99 0.48 0.54 0.65 42, 44–45, 57–58, 190, 192¶ 0.41 0.33 31.5 47.5
Trypsin/thrombin 0.41 0.59 0.46 0.39 0.65 53, 58, 189–190, 192 0.37 0.33 34.4 49.2
Trypsin/uPA 0.76 0.52 0.39 0.89 0.38 42, 57 0.35 0.28 35.2 48.3
Trypsin/tPA 0.72 0.59 0.64 0.30 0.31 42, 53, 190, 193, 195 0.38 0.38 36.9 52.5
uPA/tPA 0.26 0.23 0.28 0.57 0.06 43–45, 53–54 0.29 0.25 45.6 61.9
(b) Trypsin/apo-trypsin 0.09 0.54 0.20 0.32 0.29 190–192 0.14 0.12
Thrmb/apo-thrombin 0.17 0.56 0.25 0.12 0.61 191–192 0.27 0.25
(c) Trypsin*, P3121/P212121 0.05 0.32 0.14 0.35 0.50 192 0.13 0.12
Trypsin†, P3121/P3121 0.06 0.14 0.12 0.12 0.02 0.05 0.05
Trypsin‡, +SO4–2/–SO4–2 0.06 0.37 0.22 0.17 0.02 0.05 0.05
Differences are in Å, and sequence identity is in %. Differences greater
than 0.45 Å are in bold. In (a) and (b) all trypsin–benzamidine
comparisons involve P3121 trypsin–benzamidine-sulfate, pH 7.50,
1.21 Å resolution. Sulfate and citrate are co-bound at the active sites
of tPA– and uPA–benzamidine, respectively. *Trypsin–benzamidine,
both forms at pH 8.2, with no co-bound sulfate. The P212121 form is
the ‘small cell’ form (a = 54.8 Å, b = 58.7 Å, c = 67.6 Å).
†Trypsin–benzamidine, pH 7.0 and 7.5, sulfate co-bound at each pH.
‡Trypsin–benzamidine, both in form P3121, one at pH 7.7, with co-
bound sulfate, and the other at pH 8.25 (and otherwise identical
soaking conditions) without co-bound sulfate. §Mainchain atoms of
residues 42–45, 53–54, 57–58, 189–197, 212–221 and 227–229
were used for initial superpositions of S1, S1′ and active sites, yielding
overall initial rmsd, rmsi. Residues with significant differences in
mainchain positions between corresponding atom pairs were withheld
from final superpositions (for Figures and final comparisons), yielding
‘rmsf’. #Core residues are 26–34, 41–58, 65–71, 81–91, 102–108,
117–124, 135–144, 154–164, 180–183, 189–200, 210–215 and
226–240. ¶Also excluded were residues 193, 195, 213 and 216–219.
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Structural comparison of inhibitor complexes with
corresponding inhibitor-free enzymes
The B factors of protein groups making hydrogen bonds
with trypsin (Oδ1,2Asp189, OγSer190 and OGly219,) decrease
significantly upon inhibitor binding (Table S1b), and the
OγSer190 atom undergoes a large shift, 0.5 Å in trypsin–ben-
zamidine (Table 3b). Binding of benzamidine to thrombin
decreases the B factors of Nε2His57, Oδ1,2Asp189 and
CβAla190 (Table S1b). Binding of inhibitors to thrombin
incurs greater and more extensive structural changes than
does binding of the same inhibitors to trypsin. The rms
deviations between the superimposed inhibitor-binding
sites of thrombin–benzamidine and apo-thrombin is
0.27 Å, compared with 0.14 Å for trypsin–benzamidine/
apo-trypsin (Table 3b). Binding of benzamidine induces a
major contraction of the S1 site of thrombin, by 0.8 Å,
along the CαGlu192–CαTrp215 vector, compared with only
0.2 Å for trypsin (Table S1a). In thrombin the contraction
is reflected in a 0.6 Å change in the position of CαGlu192
(Table 3b).
The water (water1) that mediates inhibitor binding at S1 in
the complexes is bound in a similar location in the struc-
tures of apo-trypsin (Figure 4a), apo-thrombin (Figure 4b)
and apo-factor Xa. In apo-trypsin water1 makes hydrogen
bonds with OγSer190, OVal227, OTrp215, as in trypsin–benzami-
dine, and trypsin–thieno[2,3-b]pyridine-2-carboxamidine,
and makes a fourth hydrogen bond with another ordered
water (Figure 4a). Although there is a moderate increase in
mobility of this water (29 Å2) compared with that in the
complexes (B = 18–25 Å2), it is well ordered in apo-trypsin
in terms of both location and orientation.
In thrombin, water1 undergoes a more pronounced
decrease in B factor, from 16–19 Å2 to 34 Å2, upon
inhibitor binding. In apo-thrombin, water1 makes only
one hydrogen bond with the protein (with OPhe227) and
one with another water (B = 47 A2; Figure 4b). In apo-
factor Xa water1 is in a similar environment, and not well
ordered (B = 41 Å2). There are more possible orientations
of water1 in the Ala190 apo-proteases, thrombin and
factor Xa because water1 lacks the hydrogen-bonding
interactions provided by OγSer190 and OTrp215 in apo-
trypsin. Upon inhibitor binding to the Ala190 proteases,
acceptance by water1 of the hydrogen bond donated by
N1 of the inhibitor amidine causes an increase in the posi-
tional and/or rotational order of water1 (reflected by a
large decrease in B factor) that represents an unfavorable
entropy component to inhibitor binding.
Comparison of the uPA structures of this study with that
published previously
Some of the differences between the uPA structures of this
study (space group C2, resolutions up to 1.65 Å) and the
previously published structure (space group R3, 2.5 Å reso-
lution, 1lmw [13] in the Brookhaven Database [16]) occur
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Figure 3
(a) Structure of uPA–thieno[2,3-b]pyridine-
2-carboxamidine, pH 6.5, at 1.65 Å resolution,
on the (2|Fo|–|Fc|), αc map. The occupancies
of conformation 1 (with green carbons) and 2
(light green carbons) are 66% and 34%,
respectively. In the trypsin complex the
corresponding occupancies are 54% and
46% at pH 5.5, and 31% and 69% at pH 8.2.
(b) Superposition of uPA– and trypsin–
thieno[2,3-b]pyridine-2-carboxamidine,
pH 5.5. For clarity only the first conformation
of the bound inhibitors is shown. In each
complex the aromatic rings of the two bound
conformations of the inhibitors lie in the same
plane as one another (see Figure 4a). The two
locations of the Hγ proton of Ser195 for the
trypsin complex are shown.
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on the surface and are due to differences in crystal packing.
Other significant differences, however, reflect the higher
resolution and level of refinement of these new uPA struc-
tures (see Table 4 and Table S2 in the Supplementary
material section for refinement statistics). For example, in
the R3 structure the loop comprising residues 185A–186
has very high B values, > 100 Å2 for Trp186 which is com-
pletely solvent-exposed, whereas in our structure, this loop
is well determined with Trp186 well packed and well
ordered (B = 30 Å2). It was also necessary to reverse the
directionality of the A chain from that in the R3 structure
in order to fit the strong, well-defined density observed for
several residues before, after, and including the disulfide
that links the A chain to the B chain. 
Many of the asparagine and glutamine sidechains in the
R3 structure were re-oriented with respect to the flip of
the sidechain amide; of these 18 sidechains, 16 are unam-
biguously orientable because of hydrogen bonds to neigh-
boring residues. The two that are not orientable are
mobile surface residues that do not make hydrogen bonds.
Of the ten histidine sidechains, all are well determined,
and nine have unambiguous orientations with respect to
the flip of the imidazoles. 
In the C2 uPA structures of this study determined from
crystals grown in the presence of citrate, there are three
citrate molecules at intermolecular regions including one
near the active site. One acid group of the latter citrate
occupies a region near the oxyanion hole, its carboxylate
oxygens accepting a hydrogen bond from NGly193 and from
OγSer195. Another acid group makes a hydrogen-bonded
salt bridge with Nε2His57. 
Discussion
Hydrogen-bonding differences between the S1 sites of
Ser190 and Ala190 serine proteases that impart inhibitor
selectivity
Most trypsin-like serine protease targets for drug design
fall into three classes: those with serine, threonine or
alanine at position 190. The S1 sites of the Ser190 and
Ala190 sets of proteases, compared in this study, exhibit
steric and electrostatic differences that can be exploited
to engineer inhibitor selectivity. One factor contributing
to the selectivity of 4-iodobenzo[b]thiophene-2-carbox-
amidine for uPA and against tPA is an additional hydro-
gen bond between the inhibitor amidine and OγSer190 that
is absent in the Ala190 proteases. This difference in
hydrogen bonding at the S1 site is reflected in a marked
trend of greater potency of each of the four amidine
inhibitors for the Ser190 proteases than for the Ala190
counterparts (Table 1).
The more important component of the multi-centered
N1–OγSer190–water1 hydrogen-bonding network in the
uPA– and trypsin–inhibitor complexes of this study is
the N1–OγSer190 interaction. In uPA– and trypsin–
4-iodobenzo[b]thiophene-2-carboxamidine, pH 6.5 and
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Figure 4
Structures and associated (2|Fo|–|Fc|), αc
maps for (a) apo-trypsin, pH 7.7; and (b) apo-
thrombin, pH 7.5, 1.47 Å resolution. In (b), the
long water1–OTrp215 distance (3.4 Å) is
indicated in cyan.
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5.5, respectively, the N1–OγSer190 length is shorter than
the N1–water1 length by 0.5 and 0.7 Å, respectively
(Table 2). To compensate for the absence of the
N1–OγSer190 hydrogen bond in thrombin–4-iodobenzo-
[b]thiophene-2-carboxamidine, the N1–water1 hydrogen
bond is shortened, by 0.3 Å, from the value in the corre-
sponding uPA complex, and by 0.2 Å and 0.6 Å from the
values in the trypsin complex at pH 5.5 and 8.2, respec-
tively (Table 2). The N1–H1–water1 angle is nonoptimal,
130°, in both the uPA and thrombin complexes. The
single nonoptimal hydrogen bond involving H1 in throm-
bin–4-iodobenzo[b]thiophene-2-carboxamidine is, there-
fore, expected to provide less binding affinity than the
multi-centered hydrogen-bonding interactions in the cor-
responding uPA and trypsin complexes. The increase in
free energy of binding of 4-iodobenzo[b]thiophene-2-car-
boxamidine in the Ser190 proteases, can be estimated
from the ratios of the Ki values in Table 1. The increase
in free energy of binding of 4-iodobenzo[b]thiophene-2-
carboxamidine in the Ser190 proteases can be estimated
from the ratios of the Ki values in Table 1 (∆∆Gbinding in
kcal/mol for a pair of complexes with Ki values of Ki1 and
Ki2 = 1.1335× log(Ki1/Ki2)). The increase ranges from
1.4 ± 0.1 kcal/mol (for the tryptase, tPA pair) to
2.9 ± 0.2 kcal/mol (for the uPA, factor Xa pair). 
The decrease in the N1–water1 hydrogen bond length to
2.9 Å in the thrombin–4-iodobenzo[b]thiophene-2-carbox-
amidine complex from 3.2Å in the uPA complex is associ-
ated with other changes unfavorable for inhibitor binding:
a lengthening of the N1–Oδ1Asp189 hydrogen bond from
2.8 to 3.1 Å, and a change in the thiophene–amidine dihe-
dral angle from 11° to –1°. The greater planarity of the
inhibitor in the thrombin complex is associated with an
unfavorable contact between the thiophene hydrogen and
an amidine hydrogen. The resulting increase in conforma-
tional energy of the thrombin-bound inhibitor from that of
the uPA-bound inhibitor is estimated from ab initio calcu-
lations to be 0.5 kcal/mol. 
A final factor favoring the binding of 4-iodobenzo[b]thio-
phene-2-carboxamidine to uPA over Ala190 counterparts
involves the degree of order in the apo-enzymes of the
water (water1) that mediates inhibitor binding. Because
there is no hydrogen bond between water1 and the
sidechain of residue 190 in the Ala190 proteases
(Figure 4b), hydrogen-bond formation between water1
and the amidine inhibitors involves an increase in the
order (and decrease in the entropy) of water1, reflected in
a sizable decrease in its B-factor, by 15 Å2, in the case of
thrombin. In the inhibitor-free Ser190 counterparts, the
position and orientation of water1 is more constrained by
the hydrogen bond with OγSer190 (Figure 4a), and thus less
unfavorable entropy changes occur upon inhibitor
binding; the decrease in its B factor is only 4 Å2 in the case
of trypsin.
Other structural differences among the S1 sites of trypsin-
like serine proteases that impart inhibitor selectivity
In addition to the direct influence of residue 190 on the
structure and character of the S1 site, other longer-range
forces exert indirect, but significant effects. For example,
the rms mainchain positional difference, 0.35 Å, between a
set of residues (at and near S1) of the superimposed S1
sites of uPA– and trypsin–4-iodobenzo[b]thiophene-2-car-
boxamidine (each having Ser190), is similar to the corre-
sponding difference between the uPA (Ser190) and
thrombin (Ala190) complexes (0.36 Å; Table 3a). These
variations, determined by more global sequence differ-
ences (Table 3a), affect the relative locations, orientations
and dihedral angles of bound inhibitors, and consequently
the resulting hydrogen-bond lengths and van der Waals
interactions between the protease and the inhibitor. The
preference of small amidine inhibitors for Ser190 proteases
over Ala190 counterparts observed in Table 1 is not, there-
fore, expected nor observed to be completely general. 
Diversity in the binding of small amidine inhibitors at the
S1 sites of trypsin-like serine proteases
Within the set of protease–amidine complexes in this
study, there are significant differences that involve the
binding of a single inhibitor to different enzymes
(Figure 2a–c, Table 3a), as well as the binding of different
inhibitors to a single enzyme. These differences include
the relative orientations of the bound inhibitors, their
degree of planarity and their depths in the S1 pocket.
There is a corresponding variability in the relative position
and conformation of Asp189, and in the position and hydro-
gen-bonding interactions of the water co-bound at S1. 
The structures of thrombin– and tPA–benzamidine [12]
provide insight into the poor benzamidine potencies for
these proteases (Ki = 320 µM and 750 µM, respectively,
Table 1). When bound to thrombin and tPA, benzamidine
not only lacks a hydrogen bond with residue 190 (alanine
in these cases), but also has considerable conformational
strain (the phenyl-amidine dihedral is –7° in thrombin,
and –3° in tPA).
An example of how structural features other than residue
190 can influence inhibitor affinity can be seen by com-
paring the structures and associated Ki values for uPA–
and trypsin–benzamidine, both of which have serine at
position 190. The S1 site of uPA is deeper than that of
trypsin; the OγSer190–CαSer195 distance is 0.5 Å shorter in
trypsin–benzamidine than in uPA–benzamidine. The S1
site of uPA is also wider, by 0.7 Å, along the
CαAsp189–NGly226 vector (Table S1a). These enlargements
in the S1 pocket of uPA compared with that of trypsin
result in the loss of the water1–OPhe227 and water1–OTrp215
hydrogen bonds in uPA–benzamidine compared with
trypsin–benzamidine. The shift in the position of water1
in uPA–benzamidine, by 0.5 Å, from its location in
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trypsin–benzamidine, is accompanied by an unfavorable
change in the phenyl-amidine dihedral, from –20 ± 2° in
trypsin–benzamidine, to 5° in uPA–benzamidine. The
dihedral change corresponds to a calculated increase in
conformational strain of 1.9 kcal/mol, larger than the actual
decrease in binding energy of 0.9 kcal/mol calculated from
the 4.6-fold decrease in affinity (Table 1). Favorable
changes that may partially offset the conformational strain
in uPA-bound benzamidine include the significantly
shorter (by 3.3 σ and 5.0 σ, respectively) N1–OγSer190 and
water1–OγSer190 hydrogen bonds (Table 2).
Comparison of the structures of the amidine complexes of
uPA, tPA, trypsin and thrombin show, even with the sim-
plest serine protease inhibitor (benzamidine), the impor-
tant role of ordered solvent in mediating inhibitor binding,
and the intricate partitioning of structural perturbations
between changes in hydrogen bond lengths and in confor-
mational strain. In Ser190 proteases, formation of the addi-
tional enzyme–inhibitor hydrogen bond involving Ser190
concurs with other interactions, including the OηTyr228–
OγSer190 and water1–OγSer190 hydrogen bonds. These and
other short- and long-range steric and electrostatic interac-
tions at S1, determined from the local and global
sequence, are often intricately coupled and cooperatively
determine the structure and interactions of the bound
inhibitor, its conformational strain and its affinity. The
coupling renders the precise difference in the binding
energy of the multi-centered (OγSer190, water1, N1inhibitor)
hydrogen bond in Ser190 proteases versus the water1–N1
hydrogen bond in Ala190 proteases difficult to assess.
Clearly, to determine and exploit the subtle structural dif-
ferences at the S1 site that are important for inhibitor
design requires high-resolution X-ray crystal structures of
complexes involving both the target and the anti-target(s),
even when their sequences are identical and their struc-
tures highly similar in the vicinity of inhibitor binding.
Significance
Involved or implicated in numerous disease states,
trypsin-like serine proteases are rational, well-studied
targets for therapeutic inhibition. Most of these targets
and their anti-targets fall into three categories: those
with threonine, serine or alanine residues at position
190. The ability to discriminate among these protease
classes via small S1 recognition elements would provide
a powerful basis for the design of small-molecule
inhibitors that are both potent and specific for individual
drug targets, such as urokinase-type plasminogen activa-
tor (uPA).
The Ki values of 4-iodobenzo[b]thiophene-2-carboxami-
dine for uPA and for other trypsin-like serine proteases
along with the structures of the associated complexes
show that considerable specificity for uPA can be
achieved through interactions at the S1 site alone.
Although the S1 sites of uPA and tPA are highly similar
to one another, they differ at position 190: alanine in
tissue-type plasminogen activator (tPA), and serine in
uPA. Ser190 is capable of making an additional hydro-
gen bond with S1-bound amidine inhibitors that can
impart an increase in affinity of amidine inhibitors for
uPA over Ala190 counterparts.
Comparison of the structures of the S1 sites of members
of the Ala190 and Ser190 classes of trypsin-like serine
proteases indicates that these sites are as different from
one another within each class as they are between the
two classes. Structural features in addition to the
sidechain of residue 190 therefore differentiate the S1
sites of trypsin-like serine proteases and constitute a dis-
tinct fingerprint of each enzyme. Structural differences
between S1 sites formed from identical segments of local
sequence are imposed by the flanking sequence and
structure. Specificity determinants at this site reside not
only in its local structure but also in the degree and
extent of its structural plasticity, determined by the
sequence and structure of the neighboring regions. The
depth, width, electrostatic character and spatial relation-
ship of the S1 site to the active site and to other nearby
binding sites such as S1′ constitute a unique signature of
the target. When properly tuned to these parameters
remarkably small inhibitors can attain considerable
specificity.
Urokinase has emerged as a rational drug target for the
treatment of breast and prostate cancer. The uPA–
inhibitor complexes in this study are among the first
small-molecule–uPA complexes reported, and are at res-
olutions significantly higher (1.7 Å) than the previously
published uPA–peptide hemi-ketal structure (2.5 Å).
Along with the related trypsin, thrombin and factor Xa
structures described here they form part of a database
that promises to expedite structure-based design of
potent and specific small-molecule uPA inhibitors.
Materials and methods 
Preparation of deglycosylated low molecular weight human uPA
Cloning of LMW uPA. The DNA fragment coding for LMW uPA was
generated by polymerase chain reaction (PCR) amplification of
pET-20HMUK, which contains the cDNA sequence of high molecular
weight uPA (HMW uPA) cloned from a kidney cDNA population (Clon-
tech, Palo Alto, CA). The amino terminus of our recombinant LMW uPA
starts at residue 135 in the HMW uPA sequence. Amplification of LMW
uPA was performed under standard conditions with a 5′ primer (5′-
LMW-uPA = 5′-AAAAAACCGTCCTCTCCGCCGGAAGAAT-3′)
coding for the amino acids KKPSSPPEE and a 3′ primer (3′-uPA-
AvrII = 5′-CGCCTAGGTCAGAGGGCCAGGCCATTCTCTT-3′) con-
taining an Avr II restriction site (bold). The PCR-amplified product was
treated with Klenow fragment, digested with Avr II, and cloned into the
P. pastoris expression vector pPIC9K (Invitrogen, San Diego, CA) lin-
earized with SnaBI and Avr II. The sequence of LMW uPA in the expres-
sion construct (pPIC9KLMWuPA) was confirmed by sequencing.
Construction of deglycosylated LMW uPA expression vector.
Deglycosylated LMW uPA (LMW uPA-N145A) has an Asn→Ala substi-
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tution at position 302 in HMW uPA, or residue 145 of LMW uPA (chy-
motrypsin numbering scheme). The DNA fragment coding for LMW
uPA-N145A was generated by amplifying upstream and downstream of
the mutagenic site with primers, 5′-Ala-HindIII (5′-CCAAGCTTCTACC-
GACTATCTCTATCCGGAGCAGCT-3′) and 3′-Ala-Hind III (5′-CCA-
AGCTTCTTTTCCAAAGCCAGTGATCTCACA-3′) coding for the
Asn145→Ala substitution (bold type). Both mutagenic primers contain a
new Hind III site (italicized) facilitating construction of the full-length
DNA fragment coding for LMW uPA-N145A. The PCR-amplified LMW
uPA(Ala145)-HindIII product (generated with 5′-LMW-uPA and 3′-Ala-
HindIII primers) was treated with Klenow fragment and digested with
Hind III. The HindIII-uPA(Ala156)-AvrII PCR product (generated with
5′-Ala-HindIII and 3′-uPA-AvrII primers) was digested with both Hind III
and Avr II. The digested PCR fragments were then cloned into the
P. pastoris expression vector pPIC9 (Invitrogen, San Diego, CA) lin-
earized with SnaBI and Avr II. The sequence of the insert in the expres-
sion construct, pPIC9LMWuPA(N145A), was verified by sequencing.
Transformation of P. pastoris and screening for expression of
LMW uPA-N145A. The pPIC9LMWuPA(N145A) expression con-
struct was linearized with Bgl II, and used to transform the histidine-defi-
cient P. pastoris strain GS115 by electroporation as described
(P. pastoris expression kit instruction manual). Recombinant clones
were cultured in buffered glycerol-complex (BMGY) medium and
induced in buffered complex medium containing 0.5% methanol
(BMMY). Cell-free culture supernatants were isolated, and the expres-
sion of recombinant enzyme was determined by silver-stained sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) on a
12% acrylamide gel and by immunoblotting with a human uPA mono-
conal antibody (Oncogene Science). After activation with human
plasmin, enzyme activity was assayed with the chromagenic substrate,
Spectrozyme UK (American Diagnostica, Greenwich, CT). 
Purification of LMW uPA-N145A. Purification of LMW uPA-N145A
was based on affinity chromatography involving binding to p-aminoben-
zamidine [17]. Clarified P. pastoris supernatant was dialyzed into
20 mM MES (pH 6.0) with Amicon S1Y10 and passed through CM-
Sepharose (Pharmacia). Urokinase in the gradient elution fractions was
activated with plasmin at pH 8.5, 37°C for 2 h. The activated fractions
were adjusted to pH 7.0 and made 1.0 M in NaCl before loading on a
benzamidine-sepharose column (Pharmacia Biotech). Activated LMW
uPA-N145A was eluted with 100 mM citric acid (pH 3.5), giving a single
band on nonreduced SDS gel (data not shown).
Synthesis of inhibitors. Benzamidine was purchased from Sigma,
and the starting materials and reagents for other compounds from
Aldrich. 4-Iodobenzo[b]thiophene-2-carboxamidine and the corre-
sponding noniodo analog, benzo[b]thiophene-2-carboxamidine were
synthesized as described by Bridges et al. [18]. A similar procedure
[19,20] was used to synthesize thieno[2,3-b]pyridine-2-carboxamidine
(see Scheme 1 in the Supplementary material section). Synthetic
details are described in the Supplementary material section.
Enzymology
Purchased enzymes were HMW uPA (American Diagnostica), tPA
(Sigma), trypsin (Worthington), tryptase (Athens Research Technolo-
gies), thrombin (Calbiochem) and factor Xa (Haematological Technolo-
gies, Inc). The substrates for trypsin, tryptase, and thrombin
(tosyl-Gly–Pro–Lys-p-nitroanilide), for factor Xa (CH3OCO-D-CHA-
Gly–Arg-pNA-AcOH, ‘Pefachrome Xa’) and one of the two substrates
for HMW uPA (Bz-Ala–Gly–Arg-p-nitroanilide-AcOH, ‘Pefachrome UK’)
were from Centerchem, Inc. The alternative substrate for HMW uPA
(Cbz-L-(γ)Glu(α-t-BuO)-Gly-Arg-pNA, ‘Spectrozyme UK’) and the sub-
strate for tPA (CH3-SO2-D-HHT-Gly–Arg-pNA, ‘Spectrozyme tPA’)
were from American Diagostica Inc. Enzymes were assayed spec-
trophotometrically at ambient temperature in 50 mM Tris, 150 mM NaCl,
0.05% (v/v) Tween-20, 10% (v/v) DMSO, 0.002% antifoam, pH 7.4.
The thrombin and factor Xa assays also contained 5.0 mM CaCl2. The
final concentrations of uPA, tPA, trypsin, factor Xa, tryptase and throm-
bin in the respective assays were 30, 11, 7.0, 3.0, 1.0 and 6.0 nM. The
substrate concentrations of 100 µM (uPA), 200 µM (tPA), 100 µM
(trypsin), 1000 µM (factor Xa), 500 µM (tryptase) and 250 µM (throm-
bin) were chosen based on the determined Km values of 85, 430, 100,
1000, 1620 and 280 µM, respectively. The rate of change in
absorbance at 405 nm was measured immediately after addition of
enzyme. Apparent inhibition constants (K
i
′), were calculated by nonlinear
least-squares regression analysis of the absorbance time course data
using the software package BatchKi (developed and provided by Petr
Kuzmic, Biokin Ltd., Madison, Wisconsin) using methodology similar to
that described previously [21] for tight-binding inhibitors. These values
were converted to Ki values by the formula, Ki = Ki′/(1 + S/Km).
The Ki values for inhibition of each enzyme by 4-iodobenzo[b]thio-
phene-2-carboxamidine were performed under assay conditions similar
to those described above, except that concentrations of both the
inhibitor and the substrate were varied (see the Supplementary material
section), and the uPA substrate was Cbz-L-(γ)Glu(α-t-BuO)-Gly–Arg-
pNA (‘Spectrozyme UK’) from American Diagnostica. Assay data were
fitted to the equations describing competitive, noncompetitive and
uncompetitive inhibition using the computer programs COMPO, NON-
COMPO and UNCOMPO [22] and the Ki values were obtained. The
goodness of fit showed that inhibition was competitive. 
Crystallization and preparation of inhibitor-free proteases and
of protease–inhibitor complexes
Human uPA complexes. LMW human uPA-N145A was concen-
trated to 10 mg/ml using an Amicon Centricon-10 system and incu-
bated in 50 mM HEPES, 5.0 mM NaCl, pH 7.4, 1.4 mM
4-iodobenzo[b]thiophene-2-carboxamidine for 15 min on ice. Potential
crystallization conditions were screened in vapor diffusion drops with
sparse matrix screening [23] kits purchased from Hampton Research,
Laguna, CA. The complex was crystallized by vapor diffusion in hanging
drops containing equal volumes of protein–inhibitor solution (0.28 mM
LMW uPA-N145A, 1.4 mM inhibitor) and well solution (20%
2-propanol, 20% PEG 4K, 100 mM sodium citrate, pH 6.5) sealed over
the well. Diamond plate crystals grew in 2 days. Other complexes were
crystallized by a similar protocol at inhibitor concentrations at least ten-
fold higher than the Ki values.
Human thrombin–acetyl-hirudin and co-complexes. Thrombin
was purchased from Haematologic Technologies, Inc. and acetyl-hirudin
from Bachem. Thrombin-acetyl-hirudin was prepared as described previ-
ously [24]. Thrombin (1.0 mg/ml in 50 mM HEPES, 50% glycerol,
pH 7.0) was incubated with 1.0 mM acetyl-hirudin in the presence or
absence of amidine inhibitors for 1 h at 4°C. The solution contained 5
equivalents of 4-iodobenzo[b]thiophene-2-carboxamidine, 10 mM ben-
zamidine, or was saturated in [2,3-b]thienopyridine-2-carboxamidine
(~2 mM). Glycerol was removed during concentration to ~10 mg/ml of
the complexes with a centricon 10 (Amicon). Crystals of thrombin-
acetyl-hirudin with or without co-bound small molecule inhibitors, pH 7.3
or 7.8, space group C2 (a = 71.2, b = 71.8, c = 72.7 Å, β = 100.7°)
were grown in hanging drops by vapor diffusion after streak seeding.
The structure without an inhibitor at the S1 site is referred to as apo-
thrombin. The drops were made from 3 ml complex and 3 ml reservoir
solution (0.10 M HEPES, 0.30 M NaCl, 22% (by volume) PEG 5K
monomethyl ether, pH 7.5 or 8.2). Large single crystals of dimensions
>0.2 mm in each dimension grew within 1 week.
Bovine trypsin complexes and inhibitor-free trypsin. Trypsin was
crystallized as described previously [14]. A structure of P3121
trypsin–benzamidine was determined at 1.20 Å resolution, in 2.02 M
MgSO4•7 H2O, 100 mM MES, 1.0 mM CaCl2, pH 7.5. The carboxami-
dine complexes were prepared by soaking trypsin–benzamidine crys-
tals in synthetic mother liquor saturated in the inhibitors. The soaking
solutions were replaced 4 times, about once a day. For the complexes
determined at pH 8.2 the soaking solutions contained 1.73 M
MgSO4•7 H2O, 150 mM Tris, 1 mM CaCl2 and 2% dimethylsulfoxide
(DMSO). For the 4-iodobenzo[b]thiophene-2-carboxamidine complex
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at pH 5.5, the soaking solution was 85% saturated sodium citrate,
1 mM CaCl2, 2.0% DMSO, saturated with inhibitor, pH 5.5. The pH
was adjusted with saturated citric acid. For the thieno[2,3-b]pyridine-
2-carboxamidine complex, pH 5.5, the soaking solution was 1.73 M
MgSO4•7 H2O, 150 mM MES, 1 mM CaCl2, 2% DMSO. To prepare
inhibitor-free trypsin crystals, trypsin–benzamidine crystals were
soaked at the target pH values for several weeks in 1.84 M MgSO4•7
H2O, 150 mM MES or Tris, 1.0 mM CaCl2, during which the soaking
solutions were periodically replaced.
Factor Xa. Lyophilized human factor Xa was purchased from Enzyme
Research Laboratories Inc. The amino-terminal Gla-domain and car-
boxyl terminus were removed by incubation at 37°C with cathepsin G
and carboxypeptidase B, and the truncated human factor Xa purified by
high-performance liquid chromatography (HPLC) using a mono Q
HR5/5 anion exchange column, as described previously [25]. Crystals
of truncated human factor Xa (space group P3121, a = b = 81.8 Å,
c = 108.8 Å) were grown in hanging drops from equal volumes of
protein solution (5.0 mg/ml in 20 mM HEPES, 50 mM (NH4)2SO4,
pH 8.0) and well solution (25% PEG 5K, 0.10 M Hepes, 0.2 M
(NH4)2SO4, pH 7.5). The drops were sealed over the wells. Crystals
> 0.20 mm in each dimension grew after 2 weeks.
Crystallography 
Crystallographic data were collected with an R-AXIS IV image plate as
described in [14] and in the Supplementary material section. For
trypsin–benzamidine, pH 6.5, the crystal-to-detector distance was
76.0 mm, 2θ was 15.0°, and data were collected for 10 days during
which the crystal underwent minor decay. The uPA and fXa structures
were solved by molecular replacement by procedures similar to those
described previously [26] (see the Supplementary material section)
using the uPA and factor Xa structures (1lmw [13] and 1hcg [27]),
respectively, obtained from the Brookhaven Databank [16]. Initial
structures of trypsin and thrombin complexes were determined as
described previously [14], the latter from the isomorphous structure,
1hag [28], in the Brookhaven Database. Structures were refined with
X-PLOR and with difference Fourier analysis as described previously
[14,26] (see the Supplementary material section). RCSB PDB codes,
and data collection and refinement statistics, are given briefly in
Table 4, and in more detail in Table S2. 
Superposition and comparison of structures. For each pair-wise
comparison, structures were initially superimposed based on sets of S1,
S1′ and active site mainchain atoms summarized in Table 3. After inspec-
tion of the initially superimposed structures, residues were then excluded
from the superpositions in order to maximize similarities and differences in
the inhibitor-binding sites. Averages and standard deviations in hydrogen
bond lengths and other parameters were calculated for uPA–
4-iodobenzo[b]thiophene-2-carboxamidine (for which two structures were
independently determined) and for trypsin–benzamidine (for which ten
structures [14,29] in two crystal forms were independently determined at
resolutions of better than 1.5 Å resolution in this and other published and
unpublished studies. The comparisons of the two crystal forms of trypsin
in the paper involve the P212121 small-cell form (a = 54.8 Å, b = 58.7 Å,
c = 67.6 Å) and the P3121 form (a = 54.9 Å, c = 109.3 Å).
Ab initio calculations of amidine rotational barriers 
Ab initio calculations were performed on benzamidine and benzo[b]-
thiophene-2-carboxamidine with Gaussian94 [30] by the Hartree-Fock
method with the 6-31G* basis set. Geometry optimization with the
Berny algorithm [31] used redundant internal coordinates. Calculations
were carried out with no dihedral constraints or with dihedrals fixed at
values of 0°, 3°, 10°, 17° and 30°. Energies were plotted as a function
of dihedral angle to allow calculation of energy differences correspond-
ing to any changes in dihedral angles.
Research Paper  Urokinase–inhibitor crystal structures Katz et al. 311
Table 4
Crystallography of urokinase, trypsin, and thrombin complexed with benzo[b]thiophene-2-carboxamidines, thieno[2,3-b]pyridine-
2-carboxamidine, and benzamidine, and of apo-trypsin, apo-thrombin and apo-factor Xa.
RCSB PDB Code 1C5X 1C5N 1C5R 1C5Q 1C5S 1C5U 1C5T
Protease uPA Thrombin Trypsin Trypsin Trypsin Trypsin Trypsin
Inhibitor (APC #) 6860 6860 6860 6860 7377 7538 7538
pH 6.50 7.33 5.50 8.20 8.20 5.50 8.20
Rmerge (%)* 8.8 6.3 9.1 8.7 5.0 9.0 5.7
Resolution (Å) 1.75 1.50 1.47 1.43 1.36 1.37 1.37
Completeness (%) 68 65 66 75 88 81 84
Rcryst(%)† 20.2 22.2 19.7 20.0 19.9 18.4 17.9
Bond dev (Å)‡ 0.017 0.018 0.019 0.018 0.019 0.020 0.018
RCSB PDB Code 1C5P 1C5V 1C5L 1C5O 1C5Z 1C5Y 1C5M
Protease Trypsin Trypsin Thrombin Thrombin uPA uPA Factor Xa
inhibitor Benzamidine (apo) (apo) Benzamidine Benzamidine 7538 (apo)
pH 7.50 7.70 7.80 7.33 6.50 6.50 7.70
Rmerge (%)* 9.0 10.7 7.1 9.0 9.3 8.7 7.2
Resolution (Å) 1.21 1.48 1.47 1.90 1.85 1.65 1.95
Completeness (%) 88 61 69 51 64 68 60
Rcryst(%)† 19.4 20.0 21.7 20.3 18.9 20.3 22.6
Bond dev (Å)‡ 0.018 0.019 0.019 0.018 0.018 0.018 0.017
Inhibitors are coded as follows: APC-6860, 4-iodobenzo[b]thiophene-
2-carboxamidine; APC-7377, benzo[b]thiophene-2-carboxamidine;
APC-7538, thieno[2,3-b]pyridine-2-carboxamidine, . *Rmerge = ∑h∑i
|I(h)i–<I(h)i >|/∑h∑iI(h)i. †Rcryst = ∑(||Fo|–|Fc||)/∑|Fo| (for reflections from
7.5 Å to the upper resolution). ‡rmsd values from ideal bond lengths.
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Accession numbers
The atomic coordinates for these structures have been deposited with the
Protein Data Bank with the following accession codes: 1C5X uPA–APC-
6860; 1C5N, thrombin—APC-6860; 1C5R, trypsin–APC-6860; 1C5Q,
trypsin–APC-6860;1C5S, trypsin–APC-7377; 1C5U, trypsin–APC-
7538;1C5T, trypsin–APC-7538; 1C5P, trypsin–benzamidine; 1C5V,
apo-trypsin; 1C5L, apo-thrombin ; 1C5O, thrombin–benzamidine; 1C5Z,
uPA–benzamidine; 1C5Y, uPA–APC-7538; 1C5M, apo-factor Xa.
Supplementary material
Supplementary material including analysis of the discrete disorder of the
inhibitor in the uPA–thieno[2,3-b]pyridine-2-carboxamidine complex,
details of synthesis of the inhibitors, of enzymology, and of crystallogra-
phy is available at http://current-biology.com/supmat/supmatin.htm.
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